Composition suitable for diabetes mellitus, preparation method and application of composition in beverage or dairy product

Abstract

The invention belongs to the technical field of functional food, and particularly relates to a composition suitable for diabetes, a preparation method and application of the composition in beverages or dairy products. The composition suitable for diabetes mellitus comprises the following components: xylitol, pea dietary fibers, omega-3PUFAs, vitamin D and prebiotics. According to the composition suitable for diabetes mellitus provided by the invention, the content of blood sugar can be reduced by utilizing the synergistic interaction among the xylitol, the pea dietary fiber and the omega-3PUFAs; the composition also contains compound prebiotics and active ingredients of various medicinal and edible plants, so that nutritional ingredients necessary for insulin synthesis and functional factors necessary for blood glucose metabolism can be supplemented, free radicals harming a human body can be eliminated, and all the components influence each other and supplement each other.

Description

Technical Field

[0001] The present invention belongs to the technical field of functional foods, and particularly relates to a composition suitable for diabetes, a preparation method thereof, and its application in beverages or dairy products. Background Art

[0002] Diabetes is a metabolic disorder syndrome mainly characterized by high blood sugar caused by insulin deficiency or its dysfunction, mainly type II diabetes, accounting for more than 90% of the total number of diabetic patients. The treatment of diabetes generally focuses on alleviating the condition. When the treatment method is incorrect, serious complications may occur, including various cardiovascular and cerebrovascular diseases, blindness, and renal failure.

[0003] The main treatments for diabetes are to lower blood sugar with chemical drugs and supplement insulin externally. From the perspective of clinical treatment, the effect of controlling blood sugar is limited, and due to taking various drugs for a long time, there are certain side effects. Therefore, it is very important to develop daily functional foods with a certain blood sugar-lowering effect. Currently, there have been many studies and developments on the required foods.

[0004] For example, Chinese Patent Publication No. CN115944038A discloses a special solid beverage for diabetics and its preparation method. The solid beverage includes the following components in parts by weight: 85-95 parts of soybean fermented product, 3-7 parts of trace elements, and 3-7 parts of vitamins; the strains used in the fermentation process of the soybean fermented product include Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium longum, Lactobacillus bulgaricus, and Streptococcus thermophilus; the fermentation raw materials of the soybean fermented product include: culture agent, vegetable mixed solution, ammonium citrate, dipotassium hydrogen phosphate, magnesium sulfate, sodium acetate, manganese sulfate, Tween 80, and distilled water; the culture agent includes soybean powder, soybean protein powder, soybean cellulose powder, glucomannan powder, agar powder, and glucose powder. The solid beverage of this invention has a certain blood sugar-lowering effect.

[0005] Another Chinese Patent Publication No. CN119234951A discloses a medicated and edible homologous beverage for adjuvant treatment of diabetes. The beverage includes the following components: astragalus extract, pueraria extract, corn silk extract, ginseng extract, mogroside concentrated juice, and hydrogen; the hydrogen is dissolved in the beverage; preferably, the astragalus extract is astragalus polysaccharide, the pueraria extract is puerarin, the corn silk extract is corn silk peptide, and the ginseng extract is ginsenoside. This invention effectively prevents and controls blood sugar through the extracts of effective components, targeted extracts, and the addition of hydrogen, and has a significant effect on the adjuvant treatment of diabetes.

[0006] However, the diabetes-friendly beverages / milk products prepared by the above-mentioned invention patents are still suboptimal in terms of assisting in reducing blood sugar, and there are many problems such as uncertain active ingredients. Therefore, it is very important to provide a composition suitable for diabetes with better blood sugar-lowering effect. Summary of the Invention

[0007] In view of the problems existing in the prior art, the present invention provides a composition suitable for diabetes, a preparation method thereof, and its application in beverages or milk products.

[0008] To achieve the above object, the technical solution adopted by the present invention is as follows:

[0009] A composition suitable for diabetes, comprising the following components: xylitol, pea dietary fiber, ω-3 PUFAs, vitamin D, and prebiotics.

[0010] Preferably, the prebiotics comprise a mixture of mangiferin and oat glucan in a mass ratio of 1-3:2-4.

[0011] Preferably, the composition further comprises extracts of medicinal and edible homologous plants and minerals.

[0012] Preferably, the extracts of medicinal and edible homologous plants comprise one or more of green tea extract, polygonatum odoratum extract, wolfberry extract, Chinese yam extract, and ginkgo biloba extract.

[0013] Preferably, the minerals are selected from one or more of potassium chloride, calcium carbonate, ferric pyrophosphate, zinc citrate, and maltodextrin.

[0014] Preferably, by weight, the composition comprises the following components: 10-20 parts of xylitol, 10-20 parts of pea dietary fiber, 4-8 parts of ω-3 PUFAs, 0.1-0.5 part of vitamin D, 5-10 parts of prebiotics, 4-8 parts of extracts of medicinal and edible homologous plants, and 3-6 parts of minerals.

[0015] More preferably, by weight, the composition comprises the following components: 12-18 parts of xylitol, 12-16 parts of pea dietary fiber, 5-7 parts of ω-3 PUFAs, 0.2-0.4 part of vitamin D, 6-8 parts of prebiotics, 5-7 parts of extracts of medicinal and edible homologous plants, and 4-6 parts of minerals.

[0016] The present invention also provides a preparation method of the above composition, comprising the following steps: mixing xylitol, pea dietary fiber, ω-3 PUFAs, vitamin D, prebiotics, extracts of medicinal and edible homologous plants, and minerals, and then obtaining the composition.

[0017] The present invention also provides a beverage, comprising the above composition or the composition prepared by the above preparation method.

[0018] The present invention also provides a dairy product, comprising the above composition or the composition prepared by the above preparation method.

[0019] The present invention also provides the application of the above composition in beverages or dairy products.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] The composition suitable for diabetes provided by the present invention utilizes the synergistic effect among xylitol, pea dietary fiber and ω-3 PUFAs, and can reduce the blood sugar content; it also contains compound prebiotics and active ingredients of various medicinal and edible homologous plants, which can not only supplement the nutrients necessary for insulin synthesis and the functional factors necessary for blood sugar metabolism, but also scavenge free radicals that harm the human body, and the components influence and complement each other. Detailed implementation mode

[0022] It should be noted that the raw materials used in the present invention are all ordinary commercially available products. Among them, the purity of xylitol is 99%; the effective substance content of pea dietary fiber is 98%; the purity of mangiferin is ≥98%; the purity of oat glucan is ≥98%; the effective substance content of green tea extract is 90%; the effective substance content of wolfberry extract is 30:1; the effective substance content of polygonatum odoratum extract is 98%; the effective substance content of Chinese yam extract is 20:1.

[0023] Example 1

[0024] A composition suitable for diabetes, by weight, consists of the following components: 15 parts of xylitol, 12 parts of pea dietary fiber, 6 parts of ω-3 PUFAs, 0.3 part of vitamin D, 7 parts of prebiotics, 6 parts of extract of medicinal and edible homologous plants and 5 parts of minerals.

[0025] Among them, the prebiotics consist of mangiferin and oat glucan with a mass ratio of 2:3;

[0026] The extract of medicinal and edible homologous plants consists of green tea extract and wolfberry extract with a mass ratio of 2:1;

[0027] The minerals consist of zinc citrate and potassium chloride with a mass ratio of 1:1.

[0028] The preparation method of this composition is as follows: Mix xylitol, pea dietary fiber, ω-3 PUFAs, vitamin D, prebiotics, extract of medicinal and edible homologous plants and minerals, and pass through a 200-mesh sieve to obtain.

[0029] Example 2

[0030] A composition suitable for diabetes consists of the following components by weight: 12 parts of xylitol, 16 parts of pea dietary fiber, 7 parts of ω-3 PUFAs, 0.4 parts of vitamin D, 8 parts of prebiotics, 5 parts of medicinal and edible plant extracts, and 4 parts of minerals.

[0031] Among them, the prebiotics are composed of mangiferin and oat glucan in a mass ratio of 1:2;

[0032] The medicinal and edible plant extract is composed of a polygonatum extract and a wolfberry extract in a mass ratio of 1:1;

[0033] The minerals consist of calcium carbonate and maltodextrin in a mass ratio of 2:1.

[0034] The preparation method of the composition is as follows: xylitol, pea dietary fiber, ω-3PUFAs, vitamin D, prebiotics, medicinal and edible plant extracts and minerals are mixed and passed through a 200-mesh sieve to obtain the composition.

[0035] Example 3

[0036] A composition suitable for diabetes consists of the following components by weight: 20 parts of xylitol, 10 parts of pea dietary fiber, 8 parts of ω-3 PUFAs, 0.5 parts of vitamin D, 10 parts of prebiotics, 4 parts of medicinal and edible plant extracts, and 6 parts of minerals.

[0037] Among them, the prebiotics are composed of mangiferin and oat glucan in a mass ratio of 1:4;

[0038] The medicinal and edible plant extract is composed of green tea extract and yam extract in a mass ratio of 2:1;

[0039] The mineral is composed of calcium carbonate and potassium chloride in a mass ratio of 1:2.

[0040] The preparation method of the composition is as follows: xylitol, pea dietary fiber, ω-3PUFAs, vitamin D, prebiotics, medicinal and edible plant extracts and minerals are mixed and passed through a 200-mesh sieve to obtain the composition.

[0041] Example 4

[0042] A composition suitable for diabetes consists of the following components by weight: 10 parts of xylitol, 20 parts of pea dietary fiber, 4 parts of ω-3 PUFAs, 0.1 parts of vitamin D, 5 parts of prebiotics, 8 parts of medicinal and edible plant extracts, and 3 parts of minerals.

[0043] Among them, the prebiotics are composed of mangoside and oat glucan in a mass ratio of 3:2;

[0044] The medicinal and edible plant extract is composed of a polygonatum extract and a wolfberry extract in a mass ratio of 1:1;

[0045] The minerals consist of zinc citrate and maltodextrin in a mass ratio of 2:1.

[0046] The preparation method of the composition is as follows: xylitol, pea dietary fiber, ω-3PUFAs, vitamin D, prebiotics, medicinal and edible plant extracts and minerals are mixed and passed through a 200-mesh sieve to obtain the composition.

[0047] Comparative Example 1

[0048] The only difference from Example 1 is that the components do not contain xylitol, as follows:

[0049] A composition suitable for diabetes consists of the following components by weight: 22 parts of pea dietary fiber, 11 parts of ω-3 PUFAs, 0.3 parts of vitamin D, 7 parts of prebiotics, 6 parts of medicinal and edible plant extracts, and 5 parts of minerals.

[0050] Among them, the prebiotics are composed of mangoside and oat glucan in a mass ratio of 2:3;

[0051] The medicinal and edible plant extract is composed of green tea extract and wolfberry extract in a mass ratio of 2:1;

[0052] The mineral consists of zinc citrate and potassium chloride in a mass ratio of 1:1.

[0053] The preparation method of the composition is the same as that of Example 1.

[0054] Comparative Example 2

[0055] The only difference from Example 1 is that the components do not contain pea dietary fiber and ω-3 PUFAs, as follows:

[0056] A composition suitable for diabetes consists of the following components by weight: 33 parts of xylitol, 0.3 parts of vitamin D, 7 parts of prebiotics, 6 parts of medicinal and edible plant extracts, and 5 parts of minerals.

[0057] Among them, the prebiotics are composed of mangoside and oat glucan in a mass ratio of 2:3;

[0058] The medicinal and edible plant extract is composed of green tea extract and wolfberry extract in a mass ratio of 2:1;

[0059] The mineral consists of zinc citrate and potassium chloride in a mass ratio of 1:1.

[0060] The preparation method of the composition is the same as that of Example 1.

[0061] Comparative Example 3

[0062] The difference from Example 1 is that the components do not contain pea dietary fiber, which is as follows:

[0063] A composition suitable for diabetes consists of the following components by weight: 15 parts of xylitol, 18 parts of ω-3 PUFAs, 0.3 parts of vitamin D, 7 parts of prebiotics, 6 parts of medicinal and edible plant extracts, and 5 parts of minerals.

[0064] Among them, the prebiotics are composed of mangoside and oat glucan in a mass ratio of 2:3;

[0065] The medicinal and edible plant extract is composed of green tea extract and wolfberry extract in a mass ratio of 2:1;

[0066] The mineral consists of zinc citrate and potassium chloride in a mass ratio of 1:1.

[0067] The preparation method of the composition is the same as that of Example 1.

[0068] Comparative Example 4

[0069] The only difference from Example 1 is that the components do not contain ω-3 PUFAs, as follows:

[0070] A composition suitable for diabetes consists of the following components by weight: 15 parts of xylitol, 18 parts of pea dietary fiber, 0.3 parts of vitamin D, 7 parts of prebiotics, 6 parts of medicinal and edible plant extracts, and 5 parts of minerals.

[0071] Among them, the prebiotics are composed of mangoside and oat glucan in a mass ratio of 2:3;

[0072] The medicinal and edible plant extract is composed of green tea extract and wolfberry extract in a mass ratio of 2:1;

[0073] The mineral consists of zinc citrate and potassium chloride in a mass ratio of 1:1.

[0074] The preparation method of the composition is the same as that of Example 1.

[0075] Comparative Example 5

[0076] The only difference from Example 1 is that the prebiotics are composed of mangiferin and oat glucan in a mass ratio of 3:1.

[0077] A composition suitable for diabetes consists of the following components by weight: 15 parts of xylitol, 12 parts of pea dietary fiber, 6 parts of ω-3 PUFAs, 0.3 parts of vitamin D, 7 parts of prebiotics, 6 parts of medicinal and edible plant extracts, and 5 parts of minerals.

[0078] Among them, the prebiotics are composed of mangoside and oat glucan in a mass ratio of 3:1;

[0079] The medicinal and edible plant extract is composed of green tea extract and wolfberry extract in a mass ratio of 2:1;

[0080] The mineral consists of zinc citrate and potassium chloride in a mass ratio of 1:1.

[0081] The preparation method of the composition is the same as that of Example 1.

[0082] Comparative Example 6

[0083] The only difference from Example 1 is the group allocation ratio.

[0084] A composition suitable for diabetes consists of the following components by weight: 15 parts of xylitol, 5 parts of pea dietary fiber, 10 parts of ω-3 PUFAs, 0.8 parts of vitamin D, 2 parts of prebiotics, 6 parts of medicinal and edible plant extracts, and 6 parts of minerals.

[0085] Among them, the prebiotics are composed of mangoside and oat glucan in a mass ratio of 2:3;

[0086] The medicinal and edible plant extract is composed of green tea extract and wolfberry extract in a mass ratio of 2:1;

[0087] The mineral consists of zinc citrate and potassium chloride in a mass ratio of 1:1.

[0088] The preparation method of the composition is the same as that of Example 1.

[0089] Test Example 1

[0090] The compositions suitable for diabetes prepared in Examples 1-4 and Comparative Examples 1-6 were respectively subjected to hyperglycemic model hypoglycemic experiments, and the specific experimental methods are as follows:

[0091] 1. Experimental Materials

[0092] 1.1 Research subjects: compositions suitable for diabetes prepared in Examples 1-4 and Comparative Examples 1-6.

[0093] 1.2 Experimental animals: 150 SPF C57BL / 6J male mice, 4 weeks old, weighing 18-20 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., with the experimental animal production license number: SCXK (Beijing) 2016-0006. During the feeding period, the animal room was set with a 12-h light-dark cycle, and the mice had free access to food and water, and the temperature was maintained between 21-25°C and the humidity was 50-70%.

[0094] 2. Establishment of hyperglycemic model: After one week of adaptive feeding, mice were fed a high-fat diet for three weeks. At the end of the third week, they were fasted for 12 h (starting from 9:00 p.m., with free access to water during fasting), and then injected intraperitoneally in the left lower abdomen with STZ at a dose of 40 mg / kg·bw once a day for three consecutive days. At the end of the fourth week, the mice were fasted again for 12 h, and the fasting blood glucose level was measured by a rapid blood glucose meter from a tail vein blood sample. Record the food intake and water intake of the mice. Mice with a measured blood glucose level of 10 - 25 mmol / L were considered hyperglycemic model mice.

[0095] 3. Animal grouping and administration: The hyperglycemic model mice were randomly divided into 13 groups according to their blood glucose levels after fasting for 3 - 5 h, namely the high-dose group of Example 1 (administration dose 5.2 mg / g·bw), the medium-dose group of Example 1 (administration dose 2.6

[0096] mg / g·bw), the low-dose group of Example 1 (administration dose 1.3 mg / g·bw), the groups of Examples 2 - 4 (administration dose 2.6 mg / g·bw), the groups of Comparative Examples 1 - 6 (administration dose 2.6 mg / g·bw), and the model control group, with 10 mice in each group.

[0097] Normal mice were divided into a blank control group and the medium-dose group of Example 1 (administration dose 2.6 mg / g·bw), fed a normal diet and water, with 10 mice in each group.

[0098] 4. Experimental method: Each group of mice was administered by oral gavage twice (gavage volume 0.2 mL / 10 g body weight). The blank control group and the model control group were given the same volume of distilled water as the medium-dose group. Administration was continued for 30 days, and the fasting blood glucose level was measured (fasting as before the experiment), and the blood glucose levels and the percentage of blood glucose decrease in each group of animals were detected.

[0099] Percentage of blood glucose decrease = (blood glucose level before experiment - blood glucose level after experiment) ÷ blood glucose level before experiment × 100%

[0100] 5. Data analysis: The experimental results are shown in Table 1. As can be seen from Table 1, there was no statistical significance in the comparison between the medium-dose group of Example 1 and the blank control group among normal mice, indicating that the composition of the present invention has no effect on the blood glucose of normal animals. Among the hyperglycemic model mice, there were statistical differences between Examples 1 - 4 and the model control group (p < 0.05 or p < 0.01), indicating that the composition of the present invention has a blood glucose-lowering effect; among them, from Comparative Examples 1 - 4, it can be seen that by utilizing the synergistic effect among xylitol, pea dietary fiber, and ω-3 PUFAs, the blood glucose content can be effectively reduced.

[0101] Table 1 Effect of the composition of the present invention on reducing fasting blood glucose

[0102]

[0103]

[0104] Note: Compared with the blank control group, ns it indicates p > 0.05. Compared with the model control group, * it indicates p < 0.05, ** indicating p < 0.01.

[0105] Test Example 2

[0106] A human trial experiment was conducted on the composition suitable for diabetes prepared in Example 1. The specific experimental method is as follows:

[0107] 1. Subject selection:

[0108] 1.1 Inclusion criteria: Aged 18 - 65 years old, selecting individuals with impaired glucose regulation (IGR) with fasting blood glucose of 5.6 - 7 mmol / L.

[0109] 1.2 Exclusion criteria:

[0110] (1) Diabetic patients.

[0111] (2) Individuals under 18 years old or over 65 years old, pregnant or lactating women, and those allergic to the test sample.

[0112] (3) Those with complications of major organs such as the heart, liver, and kidneys, or those with other serious diseases, psychiatric patients, and those taking glucocorticoids or other drugs that affect blood glucose.

[0113] (4) Those who cannot cooperate with diet control and affect the observation results.

[0114] (5) Those with diabetic ketoacidosis and infections within the past 3 months.

[0115] (6) Those who have taken items related to the test function in the short term and affect the judgment of the results.

[0116] (7) Those who do not meet the inclusion criteria, do not take the test sample as required, or have incomplete data and affect the observation results.

[0117] 2. Experimental method: A double - blind random grouping, with two - control designs of between - group and self - control, was adopted. According to the above criteria, 120 patients with impaired glucose regulation were selected and randomly divided into 60 people in the Example 1 group and 60 people in the control group according to glycated hemoglobin and blood glucose levels. In the Example 1 group, on the basis of taking the original drug metformin as per the instructions, 3 g of the composition of Example 1 was taken 3 times a day; the control group took the drug metformin and placebo. After 2 months, the changes in clinical symptoms were observed and the number of effective people was statistically analyzed.

[0118] 3. Observation indicators

[0119] (1) Symptom observation: Inquire about the medical history in detail, understand the patient's diet and activity level, observe clinical symptoms such as excessive thirst, excessive eating, and fatigue. Statistically calculate the integral values before and after the trial food intake according to the severity of the symptoms (severe 3 points, moderate 2 points, mild 1 point), and observe the improvement rate of the main symptoms (2 points improvement for each symptom is significant, 1 point improvement is effective). The results are shown in Table 2-4.

[0120] Table 2 Statistical results of clinical symptom scores

[0121] Number Number of cases Before the trial diet After the trial diet Example 1 60 6.13±2.95 <![CDATA[3.47±1.14 *# > Control group 60 6.08±3.01 5.83±2.42

[0122] Note: Compared with before the trial food intake in Example 1, * indicates p < 0.05. Compared with after the trial food intake in the control group, # indicates p < 0.05.

[0123] Table 3 Improvement rate of clinical symptoms

[0124]

[0125] (2) Result determination

[0126] Effective: (1) Fasting blood glucose returns to normal after the test, ≤ 5.6 mmol; (2) Postprandial 2h blood glucose returns to normal after the test, ≤ 7.8 mmol.

[0127] Ineffective: The effective standard is not reached.

[0128] Table 4 Comparison of clinical efficacy

[0129] Number Number of cases Effective rate (%) Example 1 60 86.7 Control group 60 21.7

[0130] In summary, the composition suitable for diabetes provided by the present invention can reduce blood glucose content by utilizing the synergistic effect among xylitol, pea dietary fiber, and ω-3 PUFAs; it also contains compound prebiotics and active ingredients of various medicinal and edible homologous plants, which can not only supplement the necessary nutritional components for insulin synthesis and functional factors essential for blood glucose metabolism, but also scavenge free radicals that harm the human body. Each component influences and complements each other.

[0131] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than limiting the protection scope of the present invention. Any simple modification or equivalent replacement of the technical solution of the present invention by those of ordinary skill in the art does not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A composition suitable for diabetes, characterized in that, It comprises the following components: xylitol, pea dietary fiber, ω-3 PUFAs, vitamin D and prebiotics.

2. The composition according to claim 1, wherein The prebiotics comprise a mixture of mangiferin and beta-glucan in a mass ratio of 1-3:2-4.

3. The composition according to claim 1, characterized in that, The composition further comprises a medicinal and edible homologous plant extract and minerals.

4. The composition according to claim 3, characterized in that, The medicinal and edible homologous plant extract comprises one or more of green tea extract, polygonatum odoratum extract, wolfberry extract, yam extract and ginkgo biloba extract.

5. The composition according to claim 3, characterized in that, The minerals are selected from one or more of potassium chloride, calcium carbonate, ferric pyrophosphate, zinc citrate and maltodextrin.

6. The composition according to claim 3, wherein By weight, the composition comprises the following components: 10-20 parts of xylitol, 10-20 parts of pea dietary fiber, 4-8 parts of ω-3 PUFAs, 0.1-0.5 part of vitamin D, 5-10 parts of prebiotics, 4-8 parts of medicinal and edible homologous plant extract and 3-6 parts of minerals.

7. A method for preparing a composition according to any one of claims 3 - 6, characterized in that, It comprises the following steps: mixing xylitol, pea dietary fiber, ω-3 PUFAs, vitamin D, prebiotics, medicinal and edible homologous plant extract and minerals, and then the product is obtained.

8. A beverage, characterized in that, It comprises the composition according to any one of claims 1-6 or the composition prepared by the preparation method according to claim 7.

9. A dairy product, characterized in that, It comprises the composition according to any one of claims 1-6 or the composition prepared by the preparation method according to claim 7.

10. Use of the composition according to any one of claims 1-6 or the composition prepared by the preparation method according to claim 7 in beverages or dairy products.

Images